Eli Lilly said early clinical results from its acquired gene-editing therapy, VERV-102, show cholesterol reductions in participants treated at a high dose. Lilly reported a 62% reduction in cholesterol in the Phase 1 study, providing early evidence that a one-time approach could eventually target LDL lowering, a key driver of cardiovascular risk. Lilly acquired VERV-102 as part of its $1 billion buyout of Verve Therapeutics last year. The company emphasized that no treatment-related serious adverse events occurred in the Phase 1 study, a notable datapoint given that Verve had previously shelved an earlier candidate due to safety concerns. The disclosure keeps attention on the feasibility and safety profile of in vivo gene editing as a cardiovascular strategy, even as confirmatory efficacy and longer safety follow-up remain pending for any broader development pathway.